These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16806979)

  • 21. Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults.
    Waubant E; Chabas D; Okuda DT; Glenn O; Mowry E; Henry RG; Strober JB; Soares B; Wintermark M; Pelletier D
    Arch Neurol; 2009 Aug; 66(8):967-71. PubMed ID: 19667217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Voxel-wise assessment of progression of regional brain atrophy in relapsing-remitting multiple sclerosis.
    Battaglini M; Giorgio A; Stromillo ML; Bartolozzi ML; Guidi L; Federico A; De Stefano N
    J Neurol Sci; 2009 Jul; 282(1-2):55-60. PubMed ID: 19286193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study.
    Wuerfel J; Bellmann-Strobl J; Brunecker P; Aktas O; McFarland H; Villringer A; Zipp F
    Brain; 2004 Jan; 127(Pt 1):111-9. PubMed ID: 14570816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damage.
    Nessler S; Boretius S; Stadelmann C; Bittner A; Merkler D; Hartung HP; Michaelis T; Brück W; Frahm J; Sommer N; Hemmer B
    Brain; 2007 Aug; 130(Pt 8):2186-98. PubMed ID: 17617655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gadolinium-enhancing or active T2 magnetic resonance imaging lesions in multiple sclerosis clinical trials?
    Bonzano L; Roccatagliata L; Mancardi GL; Sormani MP
    Mult Scler; 2009 Sep; 15(9):1043-7. PubMed ID: 19570818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study.
    Boster A; Hreha S; Berger JR; Bao F; Penmesta R; Tselis A; Endress C; Zak I; Perumal J; Caon C; Vazquez J; Tyler KL; Racke MK; Millis S; Khan O
    Arch Neurol; 2009 May; 66(5):593-9. PubMed ID: 19433659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP; Rovaris M; Comi G; Filippi M
    Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time-series analysis of MRI intensity patterns in multiple sclerosis.
    Meier DS; Guttmann CR
    Neuroimage; 2003 Oct; 20(2):1193-209. PubMed ID: 14568488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years.
    Bagnato F; Jeffries N; Richert ND; Stone RD; Ohayon JM; McFarland HF; Frank JA
    Brain; 2003 Aug; 126(Pt 8):1782-9. PubMed ID: 12821527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of regional gray matter volume loss and progression of white matter lesions in multiple sclerosis - A longitudinal voxel-based morphometry study.
    Bendfeldt K; Kuster P; Traud S; Egger H; Winklhofer S; Mueller-Lenke N; Naegelin Y; Gass A; Kappos L; Matthews PM; Nichols TE; Radue EW; Borgwardt SJ
    Neuroimage; 2009 Mar; 45(1):60-7. PubMed ID: 19013533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
    Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tactile-associated recruitment of the cervical cord is altered in patients with multiple sclerosis.
    Agosta F; Valsasina P; Caputo D; Stroman PW; Filippi M
    Neuroimage; 2008 Feb; 39(4):1542-8. PubMed ID: 18061484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple sclerosis: chemokine receptor expression on circulating lymphocytes in correlation with radiographic measures of tissue injury.
    Fox RJ; Kivisakk P; Fisher E; Tucky B; Lee JC; Rudick RA; Ransohoff RM
    Mult Scler; 2008 Sep; 14(8):1036-43. PubMed ID: 18701575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics?
    Korteweg T; Rovaris M; Neacsu V; Filippi M; Comi G; Uitdehaag BM; Knol DL; Polman CH; Barkhof F; Vrenken H;
    Mult Scler; 2009 Apr; 15(4):465-71. PubMed ID: 19091881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study.
    Horakova D; Dwyer MG; Havrdova E; Cox JL; Dolezal O; Bergsland N; Rimes B; Seidl Z; Vaneckova M; Zivadinov R
    J Neurol Sci; 2009 Jul; 282(1-2):112-9. PubMed ID: 19168190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MRI lesion loads and disability relationships in MS: more similar than different?
    Wolinsky JS
    Neurology; 2009 Nov; 73(19):1524-5. PubMed ID: 19828867
    [No Abstract]   [Full Text] [Related]  

  • 37. Serial blood T cell repertoire alterations in multiple sclerosis patients; correlation with clinical and MRI parameters.
    Laplaud DA; Berthelot L; Miqueu P; Bourcier K; Moynard J; Oudinet Y; Guillet M; Ruiz C; Oden N; Brouard S; Guttmann CR; Weiner HL; Khoury SJ; Soulillou JP
    J Neuroimmunol; 2006 Aug; 177(1-2):151-60. PubMed ID: 16806500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of quantitative neuroimaging indices in the differentiation of ischemia from demyelination: an analytical study with case presentation.
    Hoque R; Ledbetter C; Gonzalez-Toledo E; Misra V; Menon U; Kenner M; Rabinstein AA; Kelley RE; Zivadinov R; Minagar A
    Int Rev Neurobiol; 2007; 79():491-519. PubMed ID: 17531856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Malignancy assessment of brain tumours with magnetic resonance spectroscopy and dynamic susceptibility contrast MRI.
    Fayed N; Dávila J; Medrano J; Olmos S
    Eur J Radiol; 2008 Sep; 67(3):427-33. PubMed ID: 18442889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
    Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD
    Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.